Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer

In a recent statement by AstraZeneca, AstraZeneca and Daiichi Sankyo’s antibody‑drug conjugate Datroway (datopotamab deruxtecan) has been granted Priority Review by the U.S. Food and Drug Administration (FDA) for use…

Continue Reading Datroway Receives U.S. Priority Review for First‑Line Treatment of Metastatic Triple‑Negative Breast Cancer
Antonio Cancer Team Finds New Approach for Triple Negative Breast Cancer
source: pixabay.com

Antonio Cancer Team Finds New Approach for Triple Negative Breast Cancer

An antidepressant drug that was approved by the FDA in 1959 is being put to new and promising use to fight hard-to-treat breast cancers. The antidepressant, imipramine, was approved to…

Continue Reading Antonio Cancer Team Finds New Approach for Triple Negative Breast Cancer
A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer
source: pixabay.com

A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer

Breast cancer is a result of a cell in the breast mutating and multiplying rapidly. There are over 275,000 occurrences of breast cancer in the U.S. each year. However, new…

Continue Reading A Case History of a Rheumatologist With Relapsed Leukemia and Triple-Negative Breast Cancer